SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending as the community debates its outlook ahead of earnings, with the stock drawing heavy interest from traders tracking its Pro segment performance and macro correlations to interest rates. Investors are actively weighing the impact of cooling consumer demand against potential upside from technical oversold signals and expected stability in dividend-paying assets.

Energy Vault Holdings, Inc. engages in the provision of energy storage solutions. The company was founded in September 2020 and is headquartered in Westlake Village, CA.

Energy Vault Holdings Inc

Energy Vault is currently trending as investors focus on recent strategic partnership announcements, including a major development agreement in South Africa and expansion into AI-dedicated infrastructure. While the community is actively debating the company's long-term potential versus concerns regarding dilution and volatility, sentiment remains split between bullish technical setups and frustration over recent market performance.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings is trending as investors react to a strong quarterly earnings report that featured a revenue beat and raised guidance, fueling community optimism around its AI-driven growth. Despite the positive results, active discussion reflects frustration with ongoing share price volatility and short-term selling pressure, while long-term supporters remain focused on the company's expanding enterprise partnerships and AI-powered platform adoption.

Agilysys, Inc. operates as a technology company. It offers innovative software for point-of-sale, payment gateway, reservation and table management, guest offers management, property management, inventory and procurement, analytics, document management, and mobile and wireless solutions and services to the hospitality industry. The firm also serves the gaming industry for both corporate and tribal, hotels resort and cruise, foodservice management, and the restaurant, university, and healthcare sectors. The company was founded in 1963 and is headquartered in Alpharetta, GA.

Agilysys, Inc

Agilysys is trending following a strong quarterly earnings report that featured a revenue beat and upward-revised forward guidance, fueling investor confidence in its subscription model and enterprise technology. The community is actively discussing the company's growth trajectory and momentum within the hospitality software sector, with many participants monitoring the stock for potential breakouts.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant volatility driven by a broader semiconductor sell-off and investor concerns over memory industry capacity, despite analysts recently raising price targets citing robust demand for AI infrastructure. The community remains sharply divided, with many retail investors viewing the pullback as a buying opportunity while others express anxiety over macro headwinds and potential sector overextension.

Amer Sports, Inc. engages in manufacturing, marketing, and selling sports equipment, apparel, and footwear. It operates through the following segments: Technical Apparel, Outdoor Performance, and Ball and Racquet Sports. The Technical Apparel segment refers to outdoor apparel, footwear, and accessories. It includes the Arc’teryx and Peak Performance brands. The Outdoor Performance segment focuses on outdoor apparel, footwear, accessories, and winter sports equipment. It includes the Salomon, Atomic, Armada, and ENVE brands. The Ball and Racquet Sports segment relates to sports equipment, apparel, and accessories. It includes the Wilson, Louisville Slugger, DeMarini, EvoShield, Atec, and Luxilon brands. The company was founded on January 03, 2020 and is headquartered in Helsinki, Finland.

Amer Sports Inc.

Amer Sports is trending as investors react to a strong quarterly earnings report that featured revenue growth and an upward revision to full-year guidance. The community is actively discussing the company's impressive profit margins, its portfolio of premium outdoor brands like Arc'teryx, and contrasting its performance with other consumer discretionary peers.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is experiencing significant volatility and high trading volume as investors debate its valuation relative to larger semiconductor testing peers. The community is sharply divided, with some highlighting recent contract wins and capacity expansion as signs of a long-term rerating, while others caution against the stock's parabolic move and potential for a sharp reversal.

Dominion Energy, Inc. engages in the production and distribution of energy. It operates through following business segments: Dominion Energy Virginia, Dominion Energy South Carolina, Contracted Energy, and Corporate and Other. The Corporate and Other segment focuses on corporate, service company, non-controlling interest in Dominion privatization, and non-regulated retail energy marketing operations. The company was founded by William W. Berry in 1983 and is headquartered in Richmond, VA.

Dominion Energy Inc

Dominion Energy is trending following a significant merger agreement with NextEra Energy, creating a global utility powerhouse designed to meet surging power demand from AI data centers. The community is actively debating the deal's regulatory feasibility, the potential impact on customer electricity rates, and whether the all-stock transaction represents a bargain or an overextension.

MakeMyTrip Ltd. engages in the provision of travel services. It offers air ticketing, hotels and packages, rail tickets, bus tickets, car hire, experiences and ancillary travel requirements such as foreign currency exchange services, visa processing, facilitating access to travel, and other insurance products. The company was founded by Deep Kalra and Rajesh Magow on April 28, 2000 and is headquartered in Gurgaon, India.

MakeMyTrip Ltd

MakeMyTrip is trending as investors monitor the company's strong category leadership and massive growth potential within India's expanding travel market, often drawing comparisons to other dominant global online travel agencies. While the stock has seen notable momentum and breakout patterns following solid earnings results, the community remains actively divided between those highlighting long-term structural tailwinds and those cautious of potential overvaluation or broader macroeconomic headwinds.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is experiencing significant momentum driven by a recent FDA priority review for its hypertension drug, baxdrostat, and a landmark manufacturing investment in the U.S. that has bolstered investor confidence. The community is actively discussing the stock's long-term growth potential and pipeline strength, particularly in oncology, while monitoring its strategic expansion efforts as a major player in the global pharma landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.”</li><li>As a result, the FDA no longer considers the study to be “pivotal.”</li><li>Top-line data from the 40-patient randomized, controlled study are still expected in August 2026.</li></ul> Longeveron Inc. (LGVN) shares fell 4% in after-hours trading on Friday after the U.S. Food and Drug Administration expressed reservations on the trial design for its cell therapy laromestrocel.Longeveron announced that it held a meeting with the FDA in late March 2026 to discuss the ongoing mid-stage trial of its investigational cell therapy laromestrocel in infants with hypoplastic left heart syndrome (HLHS), a severe, rare congenital heart defect where the left side of a baby's heart is severely underdeveloped and cannot properly pump blood to the body. Though the firm called the meeting ‘constructive’, investors seem more focused on the agency’s reservations about the trial’s design and its potential to support approval.<h2 class="st-heading-2">Meeting Outcomes</h2>The FDA acknowledged that HLHS is a rare, life-threatening congenital heart defect with “significant morbidity and mortality” and a high unmet medical need. However, the agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.”Longeveron said it agreed with the FDA’s assessment that the endpoint alone is insufficient. Though the company had hoped to discuss alternative or composite endpoints, the FDA indicated it could not agree to a new primary endpoint while the trial is still ongoing, it said.As a result, the FDA no longer considers the study to be “pivotal” — a designation the agency had previously discussed with the company.The release noted that the FDA is “willing to meet with Longeveron again when the ongoing ELPIS II study is completed to discuss the study results and align on a potential path forward.” Top-line data from the 40-patient randomized, controlled study are still expected in August 2026The agency emphasized that only the most objective clinical measures — all-cause mortality, cardiac transplant-free survival, events of cardiac transplantation, and well-defined major adverse cardiac events (MACE) — would be considered informative for efficacy. Longeveron said it is already capturing those endpoints, along with additional supportive measures.The company plans to submit a revised plan featuring a composite primary endpoint and secondary endpoints for FDA review. It remains “optimistic” that the full dataset, combined with other evidence, will still support an application filing after the August readout.<h2 class="st-heading-2">How Did LGVN Retail Traders React?</h2>On Stocktwits, retail sentiment around LGVN stock improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.A Stocktwits user said that they will take their loss with the company.<stembedurl>https://www.stocktwits.com/Dorps332/message/652803025</stembedurl>Another highlighted the negative takeaways from the meeting.<stembedurl>https://www.stocktwits.com/Biotech_Pharma_Investor/message/652802598</stembedurl><a href="https://stocktwits.com/symbol/LGVN">LGVN stock</a> has fallen 43% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-clocks-best-day-in-over-two-months-on-early-stage-hantavirus-vaccine-research/cZX2zB5Rego">MRNA Stock Clocks Best Day In Over Two Months On Early-Stage Hantavirus Vaccine Research</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Longeveron, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on January 3, 2025. (Photo Illustration by Jaque Silva/NurPhoto via Getty Images)

LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design

Though the firm called the meeting ‘constructive’, investors seem more focused on the agency’s reservations about the laromestrocel trial’s design and its potential to support approval.

Equity

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells Biotechs Racing to...

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. PR...

Longeveron (LGVN) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Longeveron Braces For Q4 Results Following Recent Funding Boost

Longeveron Inc. shares are trading higher Tuesday as investors pivot their focus toward the company's Q4 earnings report, due after the bell.read more...

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Longeveron shares are trading sharply higher Tuesday afternoon following the announcement of a private placement agreement worth up to $30 million.read more...

Best Biotech Stocks To Keep An Eye On - March 10th

Vertex Pharmaceuticals, BioNTech, Danaher, Longeveron, Moderna, United Therapeutics, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

<ul class="summary-bullets"><li>The company said that laromestorcel infusions resulted in clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo.</li><li>The company was evaluating whether its investigational therapy improves physical functioning in 148 ambulatory individuals with frailty.</li><li>The therapy is currently being evaluated in multiple indications including hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease (AD).</li></ul>Shares of Longeveron Inc. (LGVN) rose 7% on Wednesday, before paring back gains, after the company announced positive results from the trial of its investigational therapy in age-related clinical frailty.The company said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo, in a study.LGVN shares traded 9% lower at the time of writing.<h2 class="st-heading-2">Trial Outcomes</h2>The company said that laromestorcel infusions resulted in clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo. The 6-Minute Walk Test (6MWT) is a submaximal, standardized exercise test measuring the distance a patient can walk on a flat, hard surface in six minutes.“We are highly encouraged by these Phase 2b results that demonstrate the potential of stem cell therapy to improve the condition of patients with aging-related frailty,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.longeveron.com/news/News/news-details/2026/Longeveron-Results-of-Phase-2b-Clinical-Trial-Demonstrating-Stem-Cell-Therapy-Improved-Condition-of-Patients-with-Age-Related-Frailty-Published-in-Cell-Stem-Cell/default.aspx">said</a> Joshua M. Hare, Chief Science Officer at Longeveron. “Those with Aging Frailty are disproportionately compromised in their ability to cope with every day and acute stressors, are at high vulnerability to disease and injury, and are at increased risk for poor outcomes and death after surgery.”Laromestrocel, the company’s lead investigational product, is a human bone marrow-derived allogeneic stem cell (MSC) investigational therapy. The company was evaluating whether it improves physical functioning in 148 ambulatory individuals with frailty. The therapy is currently being evaluated in multiple indications including hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Pediatric Dilated Cardiomyopathy (DCM).<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LGVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user said that positive news from the company never helps the stock price.<stembedurl>https://www.stocktwits.com/Dorps332/message/645856800</stembedurl><a href="https://stocktwits.com/symbol/LGVN">LGVN stock</a> is down by 64% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-odd-shares-tumble-today/cZRyBHbRIGS">Why Did ODD Shares Tumble More Than 50% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study

Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

LGVN
Longeveron Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LGVN News

LGVNLongeveron Inc - Ordinary Shares - Class A